School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea.
PLoS One. 2018 Sep 18;13(9):e0204018. doi: 10.1371/journal.pone.0204018. eCollection 2018.
Polypharmacy is associated with adverse drug reactions and represents an economic burden on the health insurance system. The objective of our study was to assess the trends in polypharmacy and its associated factors in South Korea. This cross-sectional study used a nationwide sampled database between 2002 and 2013, including outpatients of all ages who received at least 1 prescription in the same period. Polypharmacy was defined as the concomitant prescription of ≥6 distinct medications on a single prescription at least once without a given duration. The yearly prescribing trends were calculated and plotted. We conducted comparative analyses to identify the changes in social gradients of polypharmacy between the first 2 years, 2002‒2003, and the final 2 years, 2012‒2013. We repeated logistic regressions for pediatrics <20 years of age and adults ≥20 years of age to estimate the adjusted odds ratios (aOR) and 95% confidence intervals (CI). The distributions of polypharmacy in the respective periods were examined according to patient economic status (0 = most deprived and 10 = most affluent). The age-standardized prevalence of polypharmacy decreased from 65.8% in 2002 to 43.7% in 2013. Our study included 1,108,298 outpatients throughout 2002-2013. Pediatric patients aged 1-9 years had the highest number of medications among all age groups (mean: 5.1 ± 1.1 in 2002-2003 vs. 4.1 ± 1.1 in 2012-2013) in both periods. Changes in the association between deprivation and polypharmacy over 10 years were observed in adults (aOR = 0.68; 95% CI = 0.62-0.75 in 2002-2003 vs. 1.60; 95% CI = 1.54-1.66 in 2012-2013) and pediatrics (aOR = 0.60; 95% CI = 0.52-0.68 in 2002-2003 vs. 1.07; 95% CI = 1.01-1.14 in 2012-2013) compared with those in the most affluent patients. The high level of polypharmacy in pediatric patients is a public health concern that warrants policymaker attention.
多药治疗与药物不良反应有关,也代表了医疗保险体系的经济负担。我们的研究目的是评估韩国多药治疗及其相关因素的趋势。这项横断面研究使用了 2002 年至 2013 年期间的全国抽样数据库,包括同期至少接受一种处方的所有年龄段的门诊患者。多药治疗定义为在同一张处方上同时开具≥6 种不同药物,且无特定持续时间。计算并绘制了每年的处方趋势。我们进行了比较分析,以确定 2002-2003 年的前 2 年和 2012-2013 年的最后 2 年之间多药治疗社会梯度的变化。我们对 20 岁以下的儿科患者和 20 岁以上的成年患者重复进行了逻辑回归,以估计调整后的优势比 (aOR) 和 95%置信区间 (CI)。根据患者的经济状况 (0=最贫困,10=最富裕),检查了各时期多药治疗的分布情况。2002 年,多药治疗的标准化患病率为 65.8%,到 2013 年降至 43.7%。我们的研究包括 2002-2013 年期间的 1108298 名门诊患者。1-9 岁的儿科患者在所有年龄组中使用的药物最多(2002-2003 年平均:5.1±1.1 vs. 2012-2013 年平均:4.1±1.1)。在成年人 (aOR=0.68;95%CI=0.62-0.75 在 2002-2003 年 vs. 1.60;95%CI=1.54-1.66 在 2012-2013 年)和儿科患者 (aOR=0.60;95%CI=0.52-0.68 在 2002-2003 年 vs. 1.07;95%CI=1.01-1.14 在 2012-2013 年)中观察到,与最富裕的患者相比,多药治疗与贫困之间的关联在过去 10 年中发生了变化。儿科患者中高水平的多药治疗是一个公共卫生问题,值得决策者关注。